JOHNSON & JOHNSON CLOSE TO $1.5 TO $2 BILLION SETTLEMENT WITH GOVERNMENT WSJ SAYS

Johnson & Johnson is close to reaching a settlement with the United States Justice Department relating to its promotion of the anti psychotic drug Risperdal for unapproved uses and could pay as much as $1.5 to $2 billion, the Wall Street Journal reports. In 2009, Pfizer agreed to pay $2.3 Billion to settle an investigation into the illegal promotion of withdrawn drug Bextra-the largest penalty to date by a drugmaker for illegal amrketing. Risperdal is approved for the treatment of schizophrenia, a bipolar disorder and irritabilityassociated with autism.

Posted in:
Updated:

One response to “JOHNSON & JOHNSON CLOSE TO $1.5 TO $2 BILLION SETTLEMENT WITH GOVERNMENT WSJ SAYS”

  1. Reg; J&J Risperdal scandal fine
    Thank you for reporting this breaking news,the atypical antipsychotic drug promoters are ‘reaping the whirlwind’.My case was with Eli Lilly Zyprexa same saga.
    Four years of off-label Zyprexa use gave me life-long diabetes.-Daniel Haszard
    FMI Google-Haszard Zyprexa

    (Risperdal is cousin of Zyprexa except that J&J is not getting any mercy because of association with family care products.)